Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Neuroblastoma 13Prostatic Neoplasms 11Leukemia 11Breast Neoplasms 11Melanoma 8Lymphoma 8Lymphoma, Non-Hodgkin 7Leukemia, Lymphocytic, Chronic, B-Cell 7Neoplasm Metastasis 6Myelodysplastic Syndromes 6Multiple Myeloma 6Leukemia, Myeloid, Acute 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Glioblastoma 5Carcinoma, Non-Small-Cell Lung 5Ovarian Neoplasms 4Lymphoma, Large B-Cell, Diffuse 4Fallopian Tube Neoplasms 4Breast Neoplasms, Male 4Lymphoma, Follicular 3Kidney Neoplasms 3Hodgkin Disease 3Glioma 3Carcinoma, Renal Cell 3Osteosarcoma 2Neoplasms, Plasma Cell 2Neoplasms 2Myeloproliferative Disorders 2Lymphoma, Mantle-Cell 2

Interventions

spartalizumab 1Granulocyte-Macrophage Colony-Stimulating Factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Objective Response Rate × Granulocyte-Macrophage Colony-Stimulating Factor × Clear all
NCT05760196 2023-03-08

Radiotherapy Combined With PD-1 Inhibitor and GM-CSF for Advanced Recurrent Metastatic Head and Neck Tumors

Renmin Hospital of Wuhan University

Phase 2 Unknown
56 enrolled

Objective Response Rate

Data powered by HemOnc (CC BY 4.0) Colophon âš¡